Literature DB >> 26776852

The clinical usefulness of 18F-fluorodeoxyglucose positron emission tomography-computed tomography (PET-CT) in follow-up of curatively resected pancreatic cancer patients.

Woohyun Jung1, Jin-Young Jang2, Mee Joo Kang1, Ye Rim Chang1, Yong Chan Shin1, Jihoon Chang1, Sun-Whe Kim1.   

Abstract

BACKGROUND: Computed tomography and serum tumor markers have limited value in detecting recurrence after curative surgery of pancreatic cancer. This study evaluated the clinical utility of 18F-fluorodeoxyglucose positron emission tomography-computed tomography (PET-CT) in diagnosing recurrence.
METHODS: One hundred ten patients underwent curative resection of pancreatic cancer were enrolled. The diagnostic value of abdominal computed tomography (CT), PET-CT and serum carbohydrate antigen (CA) 19-9 concentration were compared. The prognostic value of SUVmax on PET-CT was evaluated.
RESULTS: PET-CT showed relatively higher sensitivity (84.5% vs. 75.0%) and accuracy (84.5% vs. 74.5%) than CT, whereas PET-CT plus CT showed greater sensitivity (97.6%) and accuracy (90.0%) than either alone. In detecting distant recurrences, PET-CT showed higher sensitivity (83.1% vs. 67.7%) than CT. Nineteen patients showed recurrences only on PET-CT, with eleven having invisible or suspected benign lesions on CT, and eight had recurrences in areas not covered by CT. SUVmax over 3.3 was predictive of poor survival after recurrence.
CONCLUSIONS: PET-CT in combination with CT improves the detection of recurrence. PET-CT was especially advantageous in detecting recurrences in areas not covered by CT. If active post-operative surveillance after curative resection of pancreatic cancer is deemed beneficial, then it should include PET-CT combined with CT.
Copyright © 2015 International Hepato-Pancreato-Biliary Association Inc. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26776852      PMCID: PMC4750231          DOI: 10.1016/j.hpb.2015.06.001

Source DB:  PubMed          Journal:  HPB (Oxford)        ISSN: 1365-182X            Impact factor:   3.647


  38 in total

1.  1423 pancreaticoduodenectomies for pancreatic cancer: A single-institution experience.

Authors:  Jordan M Winter; John L Cameron; Kurtis A Campbell; Meghan A Arnold; David C Chang; Joann Coleman; Mary B Hodgin; Patricia K Sauter; Ralph H Hruban; Taylor S Riall; Richard D Schulick; Michael A Choti; Keith D Lillemoe; Charles J Yeo
Journal:  J Gastrointest Surg       Date:  2006-11       Impact factor: 3.452

2.  Role of positron emission tomography in decisions on treatment strategies for pancreatic cancer.

Authors:  Kosei Maemura; Sonshin Takao; Hiroyuki Shinchi; Hidetoshi Noma; Yukou Mataki; Hiroshi Kurahara; Seishi Jinnouchi; Takashi Aikou
Journal:  J Hepatobiliary Pancreat Surg       Date:  2006

3.  The role of paraaortic lymph node involvement on early recurrence and survival after macroscopic curative resection with extended lymphadenectomy for pancreatic carcinoma.

Authors:  Kazuaki Shimada; Yoshihiro Sakamoto; Tsuyoshi Sano; Tomoo Kosuge
Journal:  J Am Coll Surg       Date:  2006-07-21       Impact factor: 6.113

4.  Positron emission tomography/computed tomography influences on the management of resectable pancreatic cancer and its cost-effectiveness.

Authors:  Stefan Heinrich; Gerhard W Goerres; Markus Schäfer; Markus Sagmeister; Peter Bauerfeind; Bernhard C Pestalozzi; Thomas F Hany; Gustav K von Schulthess; Pierre-Alain Clavien
Journal:  Ann Surg       Date:  2005-08       Impact factor: 12.969

Review 5.  Surgery for pancreatic cancer: recent controversies and current practice.

Authors:  Curtis J Wray; Syed A Ahmad; Jeffrey B Matthews; Andrew M Lowy
Journal:  Gastroenterology       Date:  2005-05       Impact factor: 22.682

6.  Tumor relapse after pancreatic cancer resection is detected earlier by 18-FDG PET than by CT.

Authors:  Cosimo Sperti; Claudio Pasquali; Sergio Bissoli; Franca Chierichetti; Guido Liessi; Sergio Pedrazzoli
Journal:  J Gastrointest Surg       Date:  2009-09-24       Impact factor: 3.452

7.  [A case of recurrent pancreatic cancer effectively responding to S-1 combined irinotecan third-line chemotherapy with PSK].

Authors:  Osamu Saji; Masamitsu Ishii; Hiromichi Kobayashi; Ken Sumiyoshi; Takayuki Asano; Keigo Iwata; Ryuichiro Okamura; Shinjiro Kobayashi; Satoshi Koizumi; Takehito Otsubo
Journal:  Gan To Kagaku Ryoho       Date:  2013-10

8.  Role of 18F-fluorodeoxyglucose positron emission tomography imaging in surgery for pancreatic cancer.

Authors:  Hisao Wakabayashi; Yoshihiro Nishiyama; Tsuyoshi Otani; Takanori Sano; Shinichi Yachida; Keiichi Okano; Kunihiko Izuishi; Yasuyuki Suzuki
Journal:  World J Gastroenterol       Date:  2008-01-07       Impact factor: 5.742

9.  A prospective diagnostic accuracy study of 18F-fluorodeoxyglucose positron emission tomography/computed tomography, multidetector row computed tomography, and magnetic resonance imaging in primary diagnosis and staging of pancreatic cancer.

Authors:  Saila P Kauhanen; Gaber Komar; Marko P Seppänen; Kirsti I Dean; Heikki R Minn; Sami A Kajander; Irina Rinta-Kiikka; Kalle Alanen; Ronald J Borra; Pauli A Puolakkainen; Pirjo Nuutila; Jari T Ovaska
Journal:  Ann Surg       Date:  2009-12       Impact factor: 12.969

10.  PET/CT fusion scan enhances CT staging in patients with pancreatic neoplasms.

Authors:  Jeffrey M Farma; Alfredo A Santillan; Marcovalerio Melis; Janet Walters; Daly Belinc; Dung-Tsa Chen; Edward A Eikman; Mokenge Malafa
Journal:  Ann Surg Oncol       Date:  2008-06-13       Impact factor: 5.344

View more
  6 in total

1.  Application of positron emission tomography-computed tomography in the diagnosis of pulmonary ground-glass nodules.

Authors:  Lili Hu; Yuanwei Pan; Zhigang Zhou; Jianbo Gao
Journal:  Exp Ther Med       Date:  2017-09-22       Impact factor: 2.447

Review 2.  Use of Nanoparticle Contrast Agents for Cell Tracking with Computed Tomography.

Authors:  Johoon Kim; Peter Chhour; Jessica Hsu; Harold I Litt; Victor A Ferrari; Rachela Popovtzer; David P Cormode
Journal:  Bioconjug Chem       Date:  2017-05-18       Impact factor: 4.774

3.  Prognostic values of 18F-FDG PET/CT metabolic parameters and clinical figures in locally advanced pancreatic cancer underwent chemotherapy combined with stereotactic body radiation therapy.

Authors:  Anyu Zhang; Shengnan Ren; Yuan Yuan; Xiao Li; Xiaofei Zhu; Lingong Jiang; Danni Li; Changjing Zuo
Journal:  Medicine (Baltimore)       Date:  2019-03       Impact factor: 1.889

4.  Artificial Intelligence Algorithm-Based Computerized Tomography Image Features Combined with Serum Tumor Markers for Diagnosis of Pancreatic Cancer.

Authors:  Zhengmei Qiao; Junli Ge; Wenping He; Xinye Xu; Jianxin He
Journal:  Comput Math Methods Med       Date:  2022-03-02       Impact factor: 2.238

5.  The Diagnostic Performance of 18F-FDG PET/CT in Recurrent Pancreatic Cancer: A Systematic Review and Meta-analysis.

Authors:  Gu A; Yuezhan Shan; Huasong Huo; Chao Ding; Caixia Sun
Journal:  Appl Bionics Biomech       Date:  2022-06-15       Impact factor: 1.664

Review 6.  The clinical application of 18F-FDG PET/CT in pancreatic cancer: a narrative review.

Authors:  Yongzhu Pu; Chun Wang; Sheng Zhao; Ran Xie; Lei Zhao; Kun Li; Conghui Yang; Rui Zhang; Yadong Tian; Lixian Tan; Jindan Li; Shujuan Li; Long Chen; Hua Sun
Journal:  Transl Cancer Res       Date:  2021-07       Impact factor: 1.241

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.